Wells Fargo & Company Dia Medica Therapeutics Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DMAC
# of Institutions
36Shares Held
3.87MCall Options Held
1.3KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.02MShares$4.48 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$3.69 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX483KShares$2.12 Million3.48% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.68 Million0.41% of portfolio
-
Geode Capital Management, LLC Boston, MA237KShares$1.04 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $116M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...